BLINATUMOMAB | B125557 | AMGEN
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Dec. 3, 2026 | Active | Computed |
| 7-Year Orphan | Jun. 14, 1931 | Expired | Purple Book |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12415852(composition) · relevance 87/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Top 50 of 72 AI-discovered patents by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2022-01-10 | Terminated 2025-10-01 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.